Valuation: TScan Therapeutics, Inc.

Market Cap 54.18M 46.43M 43.43M 39.71M 74.94M 5.19B 75.73M 514M 200M 2.6B 203M 199M 8.62B P/E 2026 *
-0.89x
P/E 2027 * -0.82x
Enterprise Value -44.69M -38.3M -35.83M -32.76M -61.82M -4.28B -62.47M -424M -165M -2.15B -168M -164M -7.11B EV / Sales 2026 *
-7.22x
EV / Sales 2027 * -3.16x
Free-Float
93.51%
Yield 2026 *
-
Yield 2027 * -
08-19 TScan Therapeutics, Inc. And Amgen Inc. Terminate Research Collaboration And License Agreement CI
08-12 TScan Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-30 Tscan Therapeutics Doses First Patient in Phase 3 ALLOHA-2 Trial Evaluating TSC-101 in Patients with Heme Malignancies CI
06-22 TScan Therapeutics Presents Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation CI
06-22 TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment MT
06-03 Cellares and TScan Therapeutics Inc. Announce Agreement To Evaluate Automated Manufacturing Of TSC-101 CI
05-06 TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-02 TScan Therapeutics, Inc. Announces Executive Changes, Effective April 10, 2026 CI
03-04 TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
02-27 TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial RE
02-26 TScan Therapeutics, Inc. Completes Enrollment in Cohort C of Phase 1 AlloHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A03 CI
12-19 TScan Therapeutics, Inc.(NasdaqGM:TCRX) dropped from NASDAQ Biotechnology Index CI
12-07 TScan Therapeutics Announces Positive Updated Data from the AlloHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition CI
1 day+2.54%
1 week+2.02%
Current month+7.58%
1 month+0.67%
3 months-24.59%
6 months-23.88%
Current year-20.07%
1 week 0.75
Extreme 0.75
0.82
1 month 0.72
Extreme 0.716
0.87
Current year 0.72
Extreme 0.716
1.47
1 year 0.72
Extreme 0.716
2.57
3 years 0.72
Extreme 0.716
9.69
5 years 0.72
Extreme 0.716
10.76
10 years 0.72
Extreme 0.716
14.71
Manager TitleAgeSince
Chief Executive Officer 56 28/03/2023
Director of Finance/CFO 57 29/01/2024
Chief Tech/Sci/R&D Officer - 06/02/2024
Director TitleAgeSince
Director/Board Member 68 23/03/2021
Director/Board Member 56 24/05/2023
Chairman 55 12/06/2024
Date Insider Type Main position Quantity % Market Cap.
20/01/26 Free

General Counsel

350,000 0.6670%
20/01/26 Free

Chief Executive Officer

1,165,000 2.2203%
20/01/26 Free

Chief Technology Officer

420,000 0.8004%
Change 5-day change 1-year change 3-year change Capi.($)
+2.54%+2.02%-57.26%-61.39% 54.18M
-4.31%-6.62%+65.79%+98.02% 69.06B
+1.20%+0.51%+48.20%+86.36% 63.06B
-3.22%+23.17%+1.75%-5.23% 28.34B
-1.42%-3.38%-5.99%+465.34% 27.07B
+7.41%+7.45%+56.85%+17.70% 25.45B
+2.06%+2.23%+36.61%-16.40% 19.69B
+5.36%+4.61%+270.18%+415.10% 19.19B
+0.10%-3.50%+11.43%+519.16% 15.95B
+0.87%+4.26%+41.21%+150.80% 13.52B
Average +1.06%+3.15%+46.88%+166.95% 28.14B
Weighted average by Cap. -0.02%+1.66%+55.30%+153.09%

Financials

2026 *2027 *
Net sales 6.19M 5.3M 4.96M 4.54M 8.56M 593M 8.65M 58.71M 22.83M 298M 23.23M 22.73M 984M 6.51M 5.58M 5.22M 4.77M 9.01M 623M 9.1M 61.77M 24.02M 313M 24.45M 23.92M 1.04B
Net income -119M -102M -95.23M -87.06M -164M -11.37B -166M -1.13B -438M -5.71B -446M -436M -18.9B -131M -112M -105M -95.75M -181M -12.51B -183M -1.24B -482M -6.28B -490M -480M -20.78B
Net Debt -98.87M -84.73M -79.26M -72.47M -137M -9.47B -138M -938M -365M -4.75B -371M -363M -15.73B -74.76M -64.07M -59.93M -54.79M -103M -7.16B -105M -709M -276M -3.59B -281M -275M -11.89B
Logo TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
Employees
138
Date Price Change Volume
24/08/26 $0.7993 +2.54% 194,411
21/08/26 $0.7795 +0.43% 136,157
20/08/26 $0.7762 +3.49% 338,261
19/08/26 $0.7500 -9.06% 580,133
18/08/26 $0.8247 +5.26% 173,483
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.7993USD
Average target price
6.000USD
Spread / Average Target
+650.66%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRX Stock